登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>LIV-1 >LV1-H5223

Human LIV-1 / SLC39A6 Protein, His Tag

分子别名(Synonym)

SLC39A6,LIV-1,ZIP6,Zinc transporter ZIP6,ZIP-6

表达区间及表达系统(Source)

Human LIV-1, His Tag (LV1-H5223) is expressed from human 293 cells (HEK293). It contains AA Phe 29 - Trp 325 (Accession # Q13433-1).

Predicted N-terminus: Phe 29

Request for sequence

蛋白结构(Molecular Characterization)

LIV-1 Structure

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 35.5 kDa. The protein migrates as 50-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

LIV-1 SDS-PAGE

Human LIV-1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

 

活性(Bioactivity)-ELISA

LIV-1 ELISA

Immobilized Human LIV-1, His Tag (Cat. No. LV1-H5223) at 1 μg/mL (100 μL/well) can bind Anti-LIV-1 antibody, Human IgG1 with a linear range of 0.2-2 ng/mL (QC tested).

Protocol

 

活性(Bioactivity)-SPR

LIV-1 SPR

Anti-LIV-1 mAb captured on CM5 chip via anti-human IgG Fc antibody can bind Human LIV-1, His Tag (Cat. No. LV1-H5223) with an affinity constant of 5.24 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Protocol

 
评论(5)
  1. 012XXXXXXX0
  2. 3人赞
  3. When I was searching for this protein, there were not many options until I found ACRO. Very happy about various species as well as tag choices. ELISA results are reproducible and consistent. The delivery was fast whereas others may take longer. The product information is clear and comprehensive, which is very important for the research.
  4. 2022-5-1
  1. 158XXXXXXX4
  2. 0人赞
  3. 人LIV蛋白用于结合活性和亲和力筛选,之前买过,结合活性曲线趋势好,显色快,且本底值低,这次回购了十支,用于做方法验证以及后续实验的。
  4. 2023-9-5
  1. 135XXXXXXX6
  2. 0人赞
  3. 购买人源的LIV-1蛋白用于和抗体亲和力的SPR检测实验,蛋白性能比较稳定,购买了几次,每次都能重复出理想的实验,以后还会继续购买。
  4. 2022-9-22
 
ACRO质量管理体系
 
 

背景(Background)

LIV-1 is also known as SLC39A6, ZIP-6 and Zinc transporter ZIP6. May act as a zinc-influx transporter. Highly expressed in the breast, prostate, placenta, kidney, pituitary and corpus callosum. Weakly expressed in heart and intestine. Also highly expressed in cells derived from an adenocarcinoma of the cervix and lung carcinoma. Up-regulated by estrogen in breast cancer cells lines.

 

前沿进展

Optimal Selection of Lower Instrumented Vertebra Can Minimize Distal Junctional Kyphosis After Posterior Spinal Fusion for Thoracic Adolescent Idiopathic Scoliosis
Hori, Matsumura, Namikawa et al
Spine (Phila Pa 1976) (2025)
Abstract: Retrospective cohort study of a prospectively collected multicenter database.To identify risk factors for developing distal junctional kyphosis (DJK) and elucidate optimal selection of the lowest instrumented vertebra (LIV) utilizing sagittal stable vertebra (SSV) and preoperative distal junctional angle (DJA) to prevent DJK.While including the SSV may minimize DJK following posterior spinal fusion (PSF) for adolescent idiopathic scoliosis, relying solely on the SSV criteria can necessitate more extensive fusion. As LIV moves distally, a patient's motion, function, and chance of degeneration may all be negatively affected.This study included patients with Lenke 1/2 curves who underwent thoracic PSF (LIV≤L1); development of DJK (DJA≥10°) was evaluated 2 years postoperatively. Preoperative DJA was measured between LIV and LIV+1, consistent with postoperative measurements. Multiple logistic regression models identified risk factors for developing DJK. DeLong's test compared area under the curve (AUC) from different receiver operating characteristic curves to assess DJK predictive accuracy between models.Of 1,034 patients, 86 (8%) developed DJK 2 years postoperatively. Identified risk factors included preoperative DJA, LIV at ≥SSV-2, an upper instrumented vertebra of ≥T2, lumbar modifiers B or C, and larger T5-12 kyphosis. Incorporating preoperative DJA and SSV-1 for LIV selection enhanced DJK prediction accuracy over solely considering SSV inclusion (AUC=0.81 vs. 0.72, P<0.001). Furthermore, a multivariate model with risk factors achieved the highest AUC (0.87). Patients with DJK experienced worsening of T10-L2 kyphosis and lumbar lordosis over time, without affecting the Scoliosis Research Society-22 quality of life score. Among those who developed DJK, five required an extension of fixation distally.To prevent DJK, PSF should end below preoperative kyphosis and no more proximal than SSV-1 in patients with thoracic adolescent idiopathic scoliosis, particularly for high-risk cases. DJK led to kyphotic regional thoracolumbar alignment at 2-year follow-up.Level Ⅲ-retrospective comparative study.Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
Low intensity mechanical signals promote proliferation in a cell-specific manner: Tailoring a non-drug strategy to enhance biomanufacturing yields
Chan, Ashdown, Strait et al
Mechanobiol Med (2024) 2 (4)
Abstract: Biomanufacturing relies on living cells to produce biotechnology-based therapeutics, tissue engineering constructs, vaccines, and a vast range of agricultural and industrial products. With the escalating demand for these bio-based products, any process that could improve yields and shorten outcome timelines by accelerating cell proliferation would have a significant impact across the discipline. While these goals are primarily achieved using biological or chemical strategies, harnessing cell mechanosensitivity represents a promising - albeit less studied - physical pathway to promote bioprocessing endpoints, yet identifying which mechanical parameters influence cell activities has remained elusive. We tested the hypothesis that mechanical signals, delivered non-invasively using low-intensity vibration (LIV; <1 g, 10-500 Hz), will enhance cell expansion, and determined that any unique signal configuration was not equally influential across a range of cell types. Varying frequency, intensity, duration, refractory period, and daily doses of LIV increased proliferation in Chinese Hamster Ovary (CHO)-adherent cells (+79% in 96 hr) using a particular set of LIV parameters (0.2 g, 500 Hz, 3 × 30 min/d, 2 hr refractory period), yet this same mechanical input suppressed proliferation in CHO-suspension cells (-13%). Another set of LIV parameters (30 Hz, 0.7 g, 2 × 60 min/d, 2 hr refractory period) however, were able to increase the proliferation of CHO-suspension cells by 210% and T-cells by 20.3%. Importantly, we also reported that T-cell response to LIV was in-part dependent upon AKT phosphorylation, as inhibiting AKT phosphorylation reduced the proliferative effect of LIV by over 60%, suggesting that suspension cells utilize mechanism(s) similar to adherent cells to sense specific LIV signals. Particle image velocimetry combined with finite element modeling showed high transmissibility of these signals across fluids (>90%), and LIV effectively scaled up to T75 flasks. Ultimately, when LIV is tailored to the target cell population, it's highly efficient transmission across media represents a means to non-invasively augment biomanufacturing endpoints for both adherent and suspended cells, and holds immediate applications, ranging from small-scale, patient-specific personalized medicine to large-scale commercial biocentric production challenges.
Predictive Factors of Antibody-Drug Conjugate Treatment in Metastatic Breast Cancer: A Narrative Review
Gadaleta-Caldarola, Lanotte, Santoro et al
Cancers (Basel) (2024) 16 (23)
Abstract: Antibody-drug conjugates (ADCs) have revolutionized the treatment landscape for metastatic breast cancer, offering targeted delivery of cytotoxic agents with improved efficacy and tolerability compared to conventional chemotherapy. This narrative review explores key predictive factors influencing the efficacy of ADCs, focusing on HER2-targeted therapies, such as trastuzumab emtansine and trastuzumab deruxtecan, as well as sacituzumab govitecan for triple-negative breast cancer. HER2 expression, TROP-2 levels, hormone receptor status, and the tumor microenvironment emerge as critical biomarkers for patient selection and therapeutic outcomes. Additionally, we discuss resistance mechanisms, such as antigen loss, impaired drug internalization, and the role of circulating tumor DNA in predicting ADC response. Finally, future perspectives on the sequential use of ADCs and potential combination therapies are highlighted, along with emerging agents targeting alternative antigens like HER3 and LIV-1. Overall, identifying predictive biomarkers and overcoming resistance mechanisms are essential for optimizing the use of ADCs in metastatic breast cancer, thereby improving patient outcomes.
Prediction Model for Lumbar Curve Correction After Selective Thoracic Fusion in Lenke 1 and 2 Adolescent Idiopathic Scoliosis
Cai, Liu, Dai et al
Spine (Phila Pa 1976) (2024) 49 (19), 1361-1369
Abstract: A retrospective study.To identify independent risk factors and construct a prediction model for lumbar curve correction (LCC) after selective thoracic fusion (STF) in patients with Lenke 1 and 2 adolescent idiopathic scoliosis (AIS).STF has been widely applied to Lenke 1 and 2 AIS patients. However, LCC after STF is still controversial.One hundred twenty-eight patients undergoing STF with at least 2 years of follow-up were included. Cases were divided into a high-LCC group and a low-LCC group according to a rounded-up median of 65%. Forty-nine variables were taken into account. Logistic regression was applied to identify independent predictive factors. A prediction model was established by backward stepwise regression, and its evaluation was implemented on R.Five parameters showed independent predictive value for low LCC: right shoulder higher before surgery (right shoulder higher versus balanced: odds ratio [OR]=0.244, P =0.014), postoperative Cobb angle of lumbar curve (LC) (OR=1.415, P =0.001, cutoff value=11°), lowest instrumented vertebra (LIV) distal to end vertebra (no vs. yes: OR=4.587, P =0.013), postoperative LIV tilt (OR=0.686, P =0.010, cutoff value=6.85°) and postoperative LIV+1 tilt (OR=1.522, P =0.005, cutoff value=6.25°). The prediction model included 6 variables: lumbar modifier, preoperative shoulder balance, postoperative Cobb angle of LC, LIV position, postoperative LIV tilt, and postoperative LIV+1 tilt. The model evaluation demonstrated satisfactory capability and stability (area under curve=0.890, 10-fold cross-validation accuracy=0.782).Preoperative shoulder balance, Cobb angle of LC, LIV position, postoperative LIV and LIV+1 tilt could be used to prognosticate LCC after STF. A model with solid prediction ability was established, which could further our understanding of LCC and assist in making clinical decisions.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Showing 1-4 of 104 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
LIV-1靶点信息
英文全称:Zinc transporter ZIP6
中文全称:锌转运体ZIP6
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:2详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定